Hüpertriglütserideemia (Estonian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Hüpertriglütserideemia" in Estonian language version.

refsWebsite

Global rank Estonian rank

2^nd place

16^th place

4^th place

14^th place

low place

426^th place

68^th place

18^th place

1clinicaltrials.gov

5,225^th place

4,032^nd place

low place

low place

218^th place

383^rd place

1web.archive.org

1^st place

1^st place

low place

1,354^th place

cdc.gov

Centers for Disease Control and Prevention. "National Health and Nutrition Examination Survey". National Center for Health Statistics.

clinicaltrials.gov

ClinicalTrials.gov (16.03.2016). "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia". U.S. National Library of Medicine. Vaadatud 13.12.2020.

doi.org

Simha, Vinaya (2020). "Management of hypertriglyceridemia". BMJ . 371 (m3109). DOI:10.1136/bmj.m3109. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Lambert, Jennifer E.; Parks, Elizabeth J. (2012). "Postprandial metabolism of meal triglyceride in humans". Biochim Biophys Acta. 1821 (5): 721–726. DOI:10.1016/j.bbalip.2012.01.006.
Reiner, Željko (2017). "Hypertriglyceridaemia and risk of coronary artery disease". Nat Rev Cardiol. 14 (7): 401–411. DOI:10.1038/nrcardio.2017.31.
Yuan, George (2007). "Hypertriglyceridemia: its etiology, effects and treatment". CMAJ. 176 (8): 1113–1120. DOI:10.1503/cmaj.060963.
Berglund, Lars (2012). "Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 97 (9): 2969–2989. DOI:10.1210/jc.2011-3213.
Wolska, Anna (2020). "Hypertriglyceridemia: new approaches in management and treatment". Curr Opin Lipidol . 31 (6): 331–339. DOI:10.1126/scitranslmed.aaw7905. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Santos-Baez, Leinys S (2020). "Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy". Front Endocrinol (Lausanne). 11 (616). DOI:10.3389/fendo.2020.00616. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Klop, Boudewijn (2015). "Alcohol and plasma triglycerides". Curr Opin Lipidol. 24 (4): 321–326. DOI:10.1097/MOL.0b013e3283606845.
Shah, Amy S; Wilson, Don P (2015). "Primary hypertriglyceridemia in children and adolescents". J Clin Lipidol . 9 (5 Suppl): S20-28. DOI:10.1016/j.jacl.2015.04.004.
Dron, Jackqueline S.; Hegele, Robert A. (2020). "Genetics of Hypertriglyceridemia". Front Endocrinol (Lausanne). 11 (455). DOI:10.3389/fendo.2020.00455.
Villo, Ly; Risti, Robert (2020). "Calorimetric approach for comparison of Angiopoietin-like protein 4 with other pancreatic lipase inhibitors". Biochim Biophys Acta Mol Cell Biol Lipids. 1865 (2). DOI:10.1016/j.bbalip.2019.158553.
Norata, Giuseppe Danilo (2015). "Apolipoprotein C-III: From Pathophysiology to Pharmacology". Trends Pharmacol Sci. 36 (10): 675–687. DOI:10.1016/j.tips.2015.07.001.
Gaudet, Daniel (2015). "Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia". N Engl J Med. 373 (5): 438–447. DOI:10.1056/NEJMoa1400283.
Witztum, Joseph L (2019). "Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome". N Engl J Med . 381 (6): 531–542. DOI:10.1056/NEJMoa1715944. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Graham, Mark J (2017). "Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides". N Engl J Med . 377 (3): 222–232. DOI:10.1056/NEJMoa1701329.
Gaudet, Daniel (2012). "Gene therapy for lipoprotein lipase deficiency". Curr Opin Lipidol. 23 (4): 310–320. DOI:10.1097/MOL.0b013e3283555a7e.
Wang, Yan (2015). "Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion". J Lipid Res. 56 (7): 1296–1307. DOI:10.1194/jlr.M054882.
Dewey, Frederick E (2017). "Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease". N Engl J Med . 377 (3): 211–221. DOI:10.1056/NEJMoa1612790.
Amar, Marcelo J A (2015). "A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice". J Pharmacol Exp Ther. 352 (2): 227–235. DOI:10.1124/jpet.114.220418.
Sakurai, Toshihiro (2016). "Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide". J Pharmacol Exp Ther. 356 (2): 341–53. DOI:10.1124/jpet.115.229740.
Liu, Chao (2015). "Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia". Dis Model Mech. 8 (8): 989–998. DOI:10.1242/dmm.019836. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Komatsu, Tomoshiro (2019). "Apolipoprotein C-II Mimetic Peptide Promotes the Plasma Clearance of Triglyceride-Rich Lipid Emulsion and the Incorporation of Fatty Acids into Peripheral Tissues of Mice". J Nutr Metab. DOI:10.1155/2019/7078241.
Reimund, Mart; Wolska, Anna (2019). "Apolipoprotein C-II mimetic peptide is an efficient activator of lipoprotein lipase in human plasma as studied by a calorimetric approach". Biochem Biophys Res Commun. 519 (1): 67–72. DOI:10.1016/j.bbrc.2019.08.130.
Wolska, Anna (2020). "A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides". Sci Transl Med . 12 (528). DOI:10.1126/scitranslmed.aaw7905. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Meyers, Charles Daniel (2015). "Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome". Lipids Health Dis. 14 (8). DOI:10.1186/s12944-015-0006-5. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Heck, A M; Calis, K A (2000). "Orlistat, a new lipase inhibitor for the management of obesity". Pharmacotherapy. 20 (3): 270–279. DOI:10.1592/phco.20.4.270.34882.
Kenne, Foma Munoh (2017). "Plasmapheresis Treatment of Hypertriglyceridemia-Induced Acute Pancreatitis: A Case Report". Cureus. 12 (5). DOI:10.7759/cureus.8360.
Joglekar, Kiran (2017). "Therapeutic plasmapheresis for hypertriglyceridemia-associated acute pancreatitis: case series and review of the literature". Ther Adv Endocrinol Metab. 8 (4): 59–65. DOI:10.1177/2042018817695449.
Nordestgaard, Børge G (2016). "Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease". Circ Res. 118 (4): 547–563. DOI:10.1161/CIRCRESAHA.115.306249.
Carroll, Margaret D (2012). "Trends in lipids and lipoproteins in US adults, 1988–2010". JAMA. 308 (15): 1545–1554. DOI:10.1001/jama.2012.13260.
Dron, Jacqueline S (2019). "Severe hypertriglyceridemia is primarily polygenic". J Clin Lipidol. 13 (1): 80–88. DOI:10.1016/j.jacl.2018.10.006.
Kaldmäe, Margit (2017). "Prevalence of cardiovascular disease risk factors in Tallinn, Estonia". Medicina(Kaunas). 53 (4): 268–276. DOI:10.1016/j.medici.2017.07.002.

europa.eu

ema.europa.eu

"Waylivra". European Medicines Agency (EMA). Vaadatud 13.12.2020.
"Glybera". European Medicines Agency (EMA). Vaadatud 13.12.2020.

labiotech.eu

Warner, Evelyn (2017). "Goodbye Glybera! The World's First Gene Therapy will be Withdrawn". labiotech.eu. Vaadatud 13.12.2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Simha, Vinaya (2020). "Management of hypertriglyceridemia". BMJ . 371 (m3109). DOI:10.1136/bmj.m3109. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Lambert, Jennifer E.; Parks, Elizabeth J. (2012). "Postprandial metabolism of meal triglyceride in humans". Biochim Biophys Acta. 1821 (5): 721–726. DOI:10.1016/j.bbalip.2012.01.006.
Reiner, Željko (2017). "Hypertriglyceridaemia and risk of coronary artery disease". Nat Rev Cardiol. 14 (7): 401–411. DOI:10.1038/nrcardio.2017.31.
Yuan, George (2007). "Hypertriglyceridemia: its etiology, effects and treatment". CMAJ. 176 (8): 1113–1120. DOI:10.1503/cmaj.060963.
Wolska, Anna (2020). "Hypertriglyceridemia: new approaches in management and treatment". Curr Opin Lipidol . 31 (6): 331–339. DOI:10.1126/scitranslmed.aaw7905. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Santos-Baez, Leinys S (2020). "Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy". Front Endocrinol (Lausanne). 11 (616). DOI:10.3389/fendo.2020.00616. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Klop, Boudewijn (2015). "Alcohol and plasma triglycerides". Curr Opin Lipidol. 24 (4): 321–326. DOI:10.1097/MOL.0b013e3283606845.
Shah, Amy S; Wilson, Don P (2015). "Primary hypertriglyceridemia in children and adolescents". J Clin Lipidol . 9 (5 Suppl): S20-28. DOI:10.1016/j.jacl.2015.04.004.
Villo, Ly; Risti, Robert (2020). "Calorimetric approach for comparison of Angiopoietin-like protein 4 with other pancreatic lipase inhibitors". Biochim Biophys Acta Mol Cell Biol Lipids. 1865 (2). DOI:10.1016/j.bbalip.2019.158553.
Norata, Giuseppe Danilo (2015). "Apolipoprotein C-III: From Pathophysiology to Pharmacology". Trends Pharmacol Sci. 36 (10): 675–687. DOI:10.1016/j.tips.2015.07.001.
Gaudet, Daniel (2015). "Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia". N Engl J Med. 373 (5): 438–447. DOI:10.1056/NEJMoa1400283.
Witztum, Joseph L (2019). "Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome". N Engl J Med . 381 (6): 531–542. DOI:10.1056/NEJMoa1715944. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Graham, Mark J (2017). "Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides". N Engl J Med . 377 (3): 222–232. DOI:10.1056/NEJMoa1701329.
Gaudet, Daniel (2012). "Gene therapy for lipoprotein lipase deficiency". Curr Opin Lipidol. 23 (4): 310–320. DOI:10.1097/MOL.0b013e3283555a7e.
Wang, Yan (2015). "Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion". J Lipid Res. 56 (7): 1296–1307. DOI:10.1194/jlr.M054882.
Dewey, Frederick E (2017). "Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease". N Engl J Med . 377 (3): 211–221. DOI:10.1056/NEJMoa1612790.
Amar, Marcelo J A (2015). "A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice". J Pharmacol Exp Ther. 352 (2): 227–235. DOI:10.1124/jpet.114.220418.
Sakurai, Toshihiro (2016). "Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide". J Pharmacol Exp Ther. 356 (2): 341–53. DOI:10.1124/jpet.115.229740.
Liu, Chao (2015). "Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia". Dis Model Mech. 8 (8): 989–998. DOI:10.1242/dmm.019836. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Komatsu, Tomoshiro (2019). "Apolipoprotein C-II Mimetic Peptide Promotes the Plasma Clearance of Triglyceride-Rich Lipid Emulsion and the Incorporation of Fatty Acids into Peripheral Tissues of Mice". J Nutr Metab. DOI:10.1155/2019/7078241.
Reimund, Mart; Wolska, Anna (2019). "Apolipoprotein C-II mimetic peptide is an efficient activator of lipoprotein lipase in human plasma as studied by a calorimetric approach". Biochem Biophys Res Commun. 519 (1): 67–72. DOI:10.1016/j.bbrc.2019.08.130.
Wolska, Anna (2020). "A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides". Sci Transl Med . 12 (528). DOI:10.1126/scitranslmed.aaw7905. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Meyers, Charles Daniel (2015). "Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome". Lipids Health Dis. 14 (8). DOI:10.1186/s12944-015-0006-5. {{cite journal}}: kontrolli parameetri |doi= väärtust (juhend)
Heck, A M; Calis, K A (2000). "Orlistat, a new lipase inhibitor for the management of obesity". Pharmacotherapy. 20 (3): 270–279. DOI:10.1592/phco.20.4.270.34882.
Nordestgaard, Børge G (2016). "Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease". Circ Res. 118 (4): 547–563. DOI:10.1161/CIRCRESAHA.115.306249.
Carroll, Margaret D (2012). "Trends in lipids and lipoproteins in US adults, 1988–2010". JAMA. 308 (15): 1545–1554. DOI:10.1001/jama.2012.13260.
Dron, Jacqueline S (2019). "Severe hypertriglyceridemia is primarily polygenic". J Clin Lipidol. 13 (1): 80–88. DOI:10.1016/j.jacl.2018.10.006.
Kaldmäe, Margit (2017). "Prevalence of cardiovascular disease risk factors in Tallinn, Estonia". Medicina(Kaunas). 53 (4): 268–276. DOI:10.1016/j.medici.2017.07.002.

ncbi.nlm.nih.gov

Berglund, Lars (2012). "Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 97 (9): 2969–2989. DOI:10.1210/jc.2011-3213.
Dron, Jackqueline S.; Hegele, Robert A. (2020). "Genetics of Hypertriglyceridemia". Front Endocrinol (Lausanne). 11 (455). DOI:10.3389/fendo.2020.00455.
Kenne, Foma Munoh (2017). "Plasmapheresis Treatment of Hypertriglyceridemia-Induced Acute Pancreatitis: A Case Report". Cureus. 12 (5). DOI:10.7759/cureus.8360.
Joglekar, Kiran (2017). "Therapeutic plasmapheresis for hypertriglyceridemia-associated acute pancreatitis: case series and review of the literature". Ther Adv Endocrinol Metab. 8 (4): 59–65. DOI:10.1177/2042018817695449.

tai.ee

Tervise Arengu Instituut (27.05.2019). "Surmapõhjused 2018". Originaali arhiivikoopia seisuga 23.01.2021. Vaadatud 15.12.2020.

taltech.ee

digikogu.taltech.ee

Reimund, Mart (2019). "New Aspects in Stabilization and Activation Mechanisms of Lipoprotein Lipasemeetodil". Tallinna Tehnikaülikool, Loodusteaduskond, Keemia ja biotehnoloogia instituut.
Risti, Robert (2017). "Apolipoproteiin C-II analoogpeptiidi toimemehhanismi uurimine inimese vereplasmas isotermilise tiitrimis-kalorimeetria meetodil". Tallinna Tehnikaülikool, Loodusteaduskond, Keemia ja biotehnoloogia instituut.

web.archive.org

Tervise Arengu Instituut (27.05.2019). "Surmapõhjused 2018". Originaali arhiivikoopia seisuga 23.01.2021. Vaadatud 15.12.2020.